Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry.
Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry.
复制标题
DOI：
10.1016/s1470-2045(14)70364-x
复制
发表时间：
2014-12
期刊：
影响因子：
--
通讯作者：
Brown P
中科院分区：
文献类型：
--
作者：
Brewster AM;Chavez-MacGregor M;Brown P
乳腺癌发病率在全球范围内呈上升趋势，非洲血统妇女的乳腺癌相关死亡率最高，她们比欧洲血统妇女更有可能罹患基底细胞样癌或三阴性乳腺癌(TNBC)。确定使非洲裔妇女易患TNBC的文化、流行病学和遗传风险因素是一个活跃的研究领域。尽管TNBC具有侵袭性行为，但通过化疗获得病理完全缓解与良好的长期生存结果相关，而且对化疗的敏感性似乎并不因种族而异。定义TNBC异质性的分子信号分子的发现导致了靶向药物的开发，如聚(ADP-核糖)聚合酶-1和mTOR的抑制剂，以及处于临床测试早期阶段的免疫调节药物。首先，我们总结了已发表的关于非洲裔妇女和白人妇女在流行病学、生物学和对系统治疗TNBC反应方面的差异的已发表的工作，并找出一些知识上的差距。其次，我们回顾了新的治疗药物的开发机会，因为无论种族或民族血统，TNBC患者的潜在临床相关性都很高。
Breast cancer incidence is increasing worldwide, and breast cancer-related mortality is highest in women of African ancestry, who are more likely to have basal-like or triple-negative breast cancer (TNBC) than are women of European ancestry. Identification of cultural, epidemiological, and genetic risk factors that predispose women of African ancestry to TNBC is an active area of research. Despite the aggressive behaviour of TNBC, achievement of a pathological complete response with chemotherapy is associated with good long-term survival outcomes, and sensitivity to chemotherapy does not seem to differ according to ethnic origin. Discovery of the molecular signalling molecules that define TNBC heterogeneity has led to the development of targeted agents such as inhibitors of poly (ADP-ribose) polymerase-1 and mTOR and immunomodulatory drugs that are in the early stages of clinical testing. First, we summarise the existing published work on the differences reported on the epidemiology, biology, and response to systemic treatment of TNBC between women of African ancestry and white women, and identify some gaps in knowledge. Second, we review the opportunities for development of new therapeutic agents in view of the potential high clinical relevance for patients with TNBC irrespective of race or ethnic origin.